Mylan Pulls Generic Gilenya Application Over Study Concerns
As Accord Withdrawal Of Erlotinib Also Revealed By EMA's CHMP
Separate concerns raised by the EMA over bioequivalence studies have led Mylan and Accord to withdraw generic applications, including the former’s generic version of Gilenya for the treatment of multiple sclerosis.
You may also be interested in...
Shortly after announcing the launch of Bonsity (teriparatide) in the US, Pfenex and Alvogen have picked up positive opinions from the EMA’s CHMP for their teriparatide biosimilar. However, Accord Healthcare has withdrawn its own application following concerns raised by the agency.
Accord Healthcare is looking to breaking into the crowded market for biosimilar trastuzumab in the EU, after partner Henlius’ application was backed by the EMA’s CHMP. Meanwhile, a recommendation for a generic to the Eliquis anticoagulant was also forthcoming from the committee.
A year on from being spun-out of Perrigo and acquired by private equity, liquid generics specialist Rosemont Pharmaceuticals has revealed new details of the UK-based firm’s operations.